transplant did not influence NK cell numbers in our cohort and this is most probably due to the cross-sectional nature of the study. Having said this, our observational results indicate a potentially novel role for NK cells in HSCT for non-malignant disease and give an indication for further research in a larger cohort, minimizing heterogeneity.
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
The aminobisphosphonate zoledronic acid (ZA) is the most important antiresorptive agent for the treatment of multiple myeloma (MM)-related bone disease (BD). Osteonecrosis of the jaw (ONJ) is an important complication of ZA-treated MM patients (Vannucchi et al, 2005; Filleul et al, 2010) . So far, the mechanism of ONJ pathogenesis has not been clearly Re-use elucidated. Recently, a genetic susceptibility to ONJ has been suggested and a polymorphism of the cytochrome P450 CYP2C8 has been associated with ZA-related ONJ in MM (Sarasquete et al, 2008 Table II . The SNP rs1152003, mapping in PPARG, showed the strongest association with ONJ. We detected a highly significant (P = 0AE0055) differential occurrence of the C/C homozygous (HOM) genotype in 77AE7% of ONJ cases (7/9) versus only 10% of controls (1/10) ( Fig 1A) . Moreover, homozygous and heterozygous genotypes for the C variant were differently distributed between ONJ patients and the control group (Table II) . The frequency of the C variant allele in the PPARG SNP underlines a highly significant association of the C allele with the ONJ group (P = 0AE0064, Table II) . No clinical association has been previously reported for these SNPs.
Direct nucleotide sequencing was carried out on patient specimens to further confirm the presence of genetic variations, using an Applied Biosystems ABI 3100 Genetic Analyser. We found a concordance rate of 100% between DMET genotyping and sequence analysis ( Fig 1B) .
The rs1152003 SNP maps in the 3¢UTR region of PPARG, at position 12477055 of chromosome 3 (Genome Build 37.1). Although no clinical correlation has been reported for the rs1152003 variant, polymorphisms in PPARG have been associated with increased risk of a variety of diseases (Dallongeville et al, 2009) . PPARG is located in the human chromosome 3, band 3p25. Chromosomal abnormalities, such as 3p deletion, have been identified in several hematologic malignancies. PPARG is involved in adipocyte differentiation and in angiogenesis (Rosen & Spiegelman, 2001) . Recently, the PPARG pathway has been recognized as key mechanism for bone remodelling. It acts on mesenchymal stem cell differentiation by increasing adipogenesis but also inhibiting osteoblast and osteoclast formation. Moreover, PPARG polymorphisms correlate with the bone mass density (Ackert-Bicknell et al, 2008) . However, a recent study on a wide cohort of Korean individuals, with idiopathic, steroid-induced or alcoholinduced osteonecrosis of the femoral head, failed to demonstrate a significant correlation with three common PPARG polymorphisms (Kim et al, 2007) . Interestingly, modulation of PPARG activity within the bone marrow microenvironment has been recently shown to interfere with cytokines such as IL6, which is involved with a central role in the pathogenesis of MM (Wang et al, 2004) , suggesting also that PPARG may represent a valuable therapeutic target in MM (Garcia-Bates et al, 2008) .
The present study also showed that three SNPs identified in ABP1 were associated with ONJ and were in linkage disequilibrium (data not shown). ABP1 encodes a membrane glycoprotein that is expressed in many epithelial and haematopoietic tissues. Moreover, a further three ONJ-associated SNPs map to CHST11, which was recently described as a factor required for proper chondroitin sulfation and cartilage morphogenesis. Expression of the chondroitin sulfotransferase genes is crucial for the correct mammalian bone morphogenesis. Finally, the ONJ-associated rs2097937 maps to CROT, whose protein is involved in the trans-esterification of acylCoA molecules.
Our findings indicate that genetic polymorphisms are involved in the pathogenesis of ONJ in MM patients. The highly significant association of ONJ with the rs1152003 SNP polymorphism in PPARG strongly suggests this genetic variant as candidate biomarker for the identification of MM patients at risk of ONJ if treated with ZA. In fact, the C/C genotype demonstrated an odds ratio of 31AE5 (95% confidence interval, 2AE35-422AE32) for developing ONJ following ZA treatment. Differently from the recent report (Sarasquete et al, 2008) , where the study was based on the 500K Affymetrix high density array, we used the DMET platform that interrogates only highly selective SNPs associated with drug toxicity and has the advantage of avoiding an extremely high number of comparisons, which requires statistical corrections and large patient cohorts. We propose the rs1152003 C/C genotype as a candidate genetic biomarker for ONJ, which warrants validation in larger series. A phase II prospective randomized/stratified trial led by the California Cancer Consortium, and including the University of Chicago, was approved by the Cancer Therapy Evaluation Program/National Cancer Institute of the National Institutes of Health (N01-CM-62209). Patients with prior thalidomide exposure received bevacizumab alone (Arm A). Thalidomidenaïve patients were randomized to either arm B (bevacizumab alone) or C (combination therapy). The study was closed early due to poor accrual, attributable to competing trials providing access to lenalidomide and bortezomib (Knight, 2005; Lu et al, 2009; Moschetta et al, 2010) .
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The primary objectives were response rate, event-free survival, and toxicity. The secondary objective was to measure markers of angiogenesis and assess any correlation with outcome. Immunohistochemical (IHC) staining of VEGF (VG-1; Neomarkers, Freemont, CA, USA) and its two receptors, VEGFR1/Flt-1 (AB-1; Neomarkers) and VEGFR2/KDR (AB-1; Neomarkers) was carried out on bone marrow clots or cores obtained at baseline.
The study was conducted between October 2001 and November 2004. Patients aged 18 years or older, with relapsed/progressive MM and a Karnofsky performance status (KPS) >60% were enrolled. All patients signed a voluntary informed consent form, approved by the institutional review boards of the participating institutions.
Bevacizumab was given at 10 mg/kg intravenously over a 90-min period every 14 d. Thalidomide was escalated from 100 mg/d by 100 mg/week, up to 400 mg/d. Treatment cycle length was 56 d. Treatment was discontinued due to disease progression, development of grade 3 or 4 toxicities that did not resolve to grade 1 or less (maximum 3 weeks' delay was allowed), non-compliance, or patient request or physician discretion. The National Cancer Institute's Common Toxicity Criteria version 2.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf) was used for toxicity and adverse event reporting.
Complete response was defined as disappearance of the paraprotein in the serum and/or urine by immunofixation and <5% plasma cells on bone marrow evaluation. A partial remission was defined as a ‡50% reduction but still detectable level of paraprotein, and if present, a ‡50% reduction in urine M-component. Stable disease was defined as <50% reduction in paraprotein, or if the patient had light-chain disease only, a >50% reduction in the urine M-component (Bence-Jones protein). Progressive disease was defined as a 25% increase in paraprotein from the lowest level observed, measured on at least two separate occasions 2 weeks apart. We defined eventfree survival (EFS) as synonymous with time to treatment failure (TTF) to avoid reporting artificially long progressionfree survival in patients who declined further protocol therapy prior to progression. TTF was therefore defined as the time from the first day of treatment to the first observation of disease progression, death, or treatment cessation due to toxicity or patient refusal.
Fourteen patients consented; one withdrew prior to initiation of treatment, and another became ineligible due to a drop in KPS. Twelve evaluable patients, eight female, four male, (median age: 58 years, range: 50-75) were enrolled; six received bevacizumab alone (Arms A or B); six received combination therapy (Arm C). Eight of the patients were enrolled with stage III disease (Durie & Salmon, 1975) and two each with stages I and II. The median b 2 microglobulin was 2AE7 mg/l (range 1AE0-9AE9 mg/l) with nine cases of IgG j , two patients with IgG k , and one case of non-secretory myeloma. Previous treatments 
